Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

What's wrong with drug screening today

Nature Chemical Biology volume 3, pages 187–191 (2007)Cite this article

Drug screening in the immediate term will be best accomplished by early use of primary cells in which the target of the screen is a network of proteins measured in populations of single cells.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: A tangled web we weave.
Figure 2: Multicomponent network screening from discovery to clinic.

References

  1. Lou, K. & de Rond, M. Nat. Rev. Drug Discov. 5, 451–452 (2006).

    Article  CAS  Google Scholar 

  2. Mervis, J. Science 309, 726 (2005).

    Article  CAS  Google Scholar 

  3. Wood, A.J.J. N. Engl. J. Med. 355, 618–623 (2006).

    Article  CAS  Google Scholar 

  4. Krumholz, H., Ross, J., Presler, A. & Egilman, D. Br.Med. J. 334, 120–123 (20072007).

    Article  Google Scholar 

  5. Lipinski, C.A., Lombardo, F., Dominy, B.W. & Feeney, P.J. Adv. Drug Deliv. Rev. 46, 3–26 (2001).

    Article  CAS  Google Scholar 

  6. Irish, J.M. et al. Cell 118, 217–228 (2004).

    Article  CAS  Google Scholar 

  7. Sachs, K., Perez, O., Pe'er, D., Lauffenburger, D.A. & Nolan, G.P. Science 308, 523–529 (2005).

    Article  CAS  Google Scholar 

  8. Perez, O.D. & Nolan, G.P. Nat. Biotechnol. 20, 155–162 (2002).

    Article  CAS  Google Scholar 

  9. Krutzik, P.O. & Nolan, G.P. Cytometry A 55, 61–70 (2003).

    Article  Google Scholar 

  10. Krutzik, P.O. & Nolan, G.P. Nat. Methods 3, 361–368 (2006).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Garry P. Nolan is in the Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California 94305, USA. gnolan@stanford.edu,

    Garry P Nolan

Authors
  1. Garry P Nolan
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

G.P.N. is the chair of the science advisory board of a molecular diagnostics company and a holder of equity in this company. G.P.N. also advises (i) a large pharmaceutical company that is creating molecular diagnostics and (ii) a drug screening company on screening approaches.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nolan, G. What's wrong with drug screening today. Nat Chem Biol 3, 187–191 (2007). https://doi.org/10.1038/nchembio0407-187

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nchembio0407-187

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing